543 related articles for article (PubMed ID: 9368550)
1. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group.
Stroke; 1997 Nov; 28(11):2109-18. PubMed ID: 9368550
[TBL] [Abstract][Full Text] [Related]
2. Tissue plasminogen activator for acute ischemic stroke.
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group
N Engl J Med; 1995 Dec; 333(24):1581-7. PubMed ID: 7477192
[TBL] [Abstract][Full Text] [Related]
3. Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice.
Chiu D; Krieger D; Villar-Cordova C; Kasner SE; Morgenstern LB; Bratina PL; Yatsu FM; Grotta JC
Stroke; 1998 Jan; 29(1):18-22. PubMed ID: 9445322
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke: pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II Trials.
Cucchiara B; Kasner SE; Tanne D; Levine SR; Demchuk A; Messe SR; Sansing L; Lees KR; Lyden P;
Stroke; 2009 Sep; 40(9):3067-72. PubMed ID: 19608993
[TBL] [Abstract][Full Text] [Related]
5. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
[TBL] [Abstract][Full Text] [Related]
6. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS).
Hacke W; Kaste M; Fieschi C; Toni D; Lesaffre E; von Kummer R; Boysen G; Bluhmki E; Höxter G; Mahagne MH
JAMA; 1995 Oct; 274(13):1017-25. PubMed ID: 7563451
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke.
Broderick J; Lu M; Jackson C; Pancioli A; Tilley BC; Fagan SC; Kothari R; Levine SR; Marler JR; Lyden PD; Haley EC; Brott T; Grotta JC;
Ann Neurol; 2001 Jun; 49(6):736-44. PubMed ID: 11409425
[TBL] [Abstract][Full Text] [Related]
8. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke.
Patel SC; Levine SR; Tilley BC; Grotta JC; Lu M; Frankel M; Haley EC; Brott TG; Broderick JP; Horowitz S; Lyden PD; Lewandowski CA; Marler JR; Welch KM;
JAMA; 2001 Dec; 286(22):2830-8. PubMed ID: 11735758
[TBL] [Abstract][Full Text] [Related]
9. Hyperacute stroke therapy with tissue plasminogen activator.
Alberts MJ
Am J Cardiol; 1997 Aug; 80(4C):29D-34D; discussion 35D-39D. PubMed ID: 9284041
[TBL] [Abstract][Full Text] [Related]
10. The THRIVE score predicts symptomatic intracerebral hemorrhage after intravenous tPA administration in SITS-MOST.
Flint AC; Gupta R; Smith WS; Kamel H; Faigeles BS; Cullen SP; Rao VA; Bath PM; Wahlgren N; Ahmed N; Donnan GA;
Int J Stroke; 2014 Aug; 9(6):705-10. PubMed ID: 25042855
[TBL] [Abstract][Full Text] [Related]
11. Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial.
Stroke; 1997 Nov; 28(11):2119-25. PubMed ID: 9368551
[TBL] [Abstract][Full Text] [Related]
12. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism.
del Zoppo GJ; Higashida RT; Furlan AJ; Pessin MS; Rowley HA; Gent M
Stroke; 1998 Jan; 29(1):4-11. PubMed ID: 9445320
[TBL] [Abstract][Full Text] [Related]
13. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000.
Grotta JC; Burgin WS; El-Mitwalli A; Long M; Campbell M; Morgenstern LB; Malkoff M; Alexandrov AV
Arch Neurol; 2001 Dec; 58(12):2009-13. PubMed ID: 11735774
[TBL] [Abstract][Full Text] [Related]
14. Should we exclude acute stroke patients with previous intracerebral hemorrhage from receiving intravenous thrombolysis?
Lee SH; Kim BJ; Han MK; Park TH; Lee KB; Lee BC; Yu KH; Oh MS; Cha JK; Kim DH; Nah HW; Lee J; Lee SJ; Ko Y; Kim JG; Park JM; Kang K; Cho YJ; Hong KS; Choi JC; Kim JT; Choi K; Kim DE; Ryu WS; Kim WJ; Shin DI; Yeo M; Lee J; Lee JS; Gorelick PB; Bae HJ
Int J Stroke; 2016 Oct; 11(7):783-90. PubMed ID: 27312681
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment hemostatic markers of symptomatic intracerebral hemorrhage in patients treated with tissue plasminogen activator.
Cocho D; Borrell M; Martí-Fàbregas J; Montaner J; Castellanos M; Bravo Y; Molina-Porcel L; Belvís R; Díaz-Manera JA; Martínez-Domeño A; Martínez-Lage M; Millán M; Fontcuberta J; Martí-Vilalta JL
Stroke; 2006 Apr; 37(4):996-9. PubMed ID: 16497981
[TBL] [Abstract][Full Text] [Related]
16. Dosing errors did not have a major impact on outcome in the NINDS t-PA stroke study.
Messé SR; Kasner SE; Cucchiara BL; Demchuk A; Tanne D; Ouyang B; Levine SR;
J Stroke Cerebrovasc Dis; 2011; 20(3):236-40. PubMed ID: 20656508
[TBL] [Abstract][Full Text] [Related]
17. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience.
National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group
Ann Emerg Med; 2005 Sep; 46(3):243-52. PubMed ID: 16126134
[TBL] [Abstract][Full Text] [Related]
18. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke.
Demchuk AM; Morgenstern LB; Krieger DW; Linda Chi T; Hu W; Wein TH; Hardy RJ; Grotta JC; Buchan AM
Stroke; 1999 Jan; 30(1):34-9. PubMed ID: 9880385
[TBL] [Abstract][Full Text] [Related]
19. Leukoaraiosis, Cerebral Hemorrhage, and Outcome After Intravenous Thrombolysis for Acute Ischemic Stroke: A Meta-Analysis (v1).
Charidimou A; Pasi M; Fiorelli M; Shams S; von Kummer R; Pantoni L; Rost N
Stroke; 2016 Sep; 47(9):2364-72. PubMed ID: 27491738
[TBL] [Abstract][Full Text] [Related]
20. Hemorrhage in the Interventional Management of Stroke study.
IMS Study Investigators
Stroke; 2006 Mar; 37(3):847-51. PubMed ID: 16439694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
